Table 2.
Eradication rate over the first treatment during the periods without (June, 2004 to October, 2005) and with (November, 2005 to August, 2010) a routine genetic test for CYP2C19
| Subjects | 2004–2005 | 2005–2010 | |||
| Untested | *1*1 | Other genotypes | Untested* | Total | |
| n (%) | n (%) | n (%) | n (%) | n (%) | |
| Visited | 195 (100) | - | - | - | 284 (100) |
| Infected | 130 (66.7) | 66 | 126 | 3 | 195 (68.7) |
| Treated | 114 | 60 | 118 | 3 | 181 |
| Succeeded | 72 (80.0**) | 49 (100.0**) | 60 (82.2**) | 1(50.0) | 110 (88.7**) |
| Failed | 18 (20.0**) | 0 | 13 (17.8**) | 1(50.0) | 14 (11.3**) |
| Not evaluated | 24 | 11 | 45 | 1 | 57 |
| Re-treated | 12 | - | 12 | 1 | 13 |
| Succeeded | 7 (87.5**) | - | 9 (90.0) | - | 9 (90.0**) |
| Failed | 1 (12.5**) | - | 1 (10.0) | - | 1 (10.0**) |
| Not evaluated | 4 | - | 2 | 1 | 3 |
*Untested before prescription
** Rate excluding those unevaluated